Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuralized E3 ubiquitin protein ligase 4 (NEURL4) is a centriolar protein belonging to the Neuralized family, characterized by E3 ubiquitin ligase activity. It primarily localizes to the daughter centriole and interacts with CP110, promoting its ubiquitination and subsequent proteasomal degradation. This post-translational modification of CP110 by NEURL4 is essential for the maintenance of centriolar homeostasis and prevention of ectopic microtubule-organizing centers, thereby ensuring normal cell division and centrosome function. Loss or depletion of NEURL4 leads to accumulation of CP110, formation of aberrant centrosome structures, and mitotic defects, which are processes relevant to cellular genomic stability but not directly targeted by current therapeutics[1][2][7].
Modulation of NEURL4 would theoretically alter CP110 ubiquitination and centriolar homeostasis, but no approved drugs or clinical interventions are known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuralized E3 ubiquitin protein ligase 4 (NEURL4).